Cumberland Pharmaceuticals Inc. (CPIX)
Market Cap | 24.10M |
Revenue (ttm) | 39.55M |
Net Income (ttm) | -6.28M |
Shares Out | 14.18M |
EPS (ttm) | -0.44 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 101 |
Open | 1.700 |
Previous Close | 1.610 |
Day's Range | 1.610 - 1.700 |
52-Week Range | 1.430 - 2.360 |
Beta | 0.17 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | May 7, 2024 |
About CPIX
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infect... [Read more]
Full Company ProfileFinancial Performance
In 2023, CPIX's revenue was $39.55 million, a decrease of -5.85% compared to the previous year's $42.01 million. Losses were -$6.28 million, 12.7% more than in 2022.
Financial StatementsNews
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants NASHVILLE, Tenn. , April 2, 2024 /PRNewswire/ -- Cumberland Pharmaceu...
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
2023 highlights include expanded FDA approval and new study publications NASHVILLE, Tenn. , March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical com...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS
NASHVILLE, Tenn. , Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial res...
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
NASHVILLE, Tenn. , Nov. 7, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands de...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
NASHVILLE, Tenn., Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financi...
NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE
NASHVILLE, Tenn. , Oct. 10, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy 1 detailing the results of th...
Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023
NASHVILLE, Tenn. , Aug. 8, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favor...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
NASHVILLE, Tenn. , Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financ...
NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS
NASHVILLE, Tenn. , June 26, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the publication of positive results from a clinical...
CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Cumberland initiating Phase II FIGHTING FIBROSIS™ clinical trial, Newest program in Cumberland's ifetroban pipeline NASHVILLE, Tenn. , May 23, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nas...
CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS
Caldolor® is the only injectable non-opioid approved for treating pain in infants NASHVILLE, Tenn. , May 15, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceut...
Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update
NASHVILLE, Tenn. , May 9, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that the Company's product portfolio of FDA-approved ...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS
NASHVILLE, Tenn. , May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2023 financia...
CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022
2022 highlights include its acquisition of Sancuso ® and move to new headquarters NASHVILLE, Tenn. , March 7, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceu...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS
NASHVILLE, Tenn. , Feb. 28, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022 financial res...
Cumberland Pharmaceuticals Reports 41% Revenue Growth
Company Also Delivers Growing Cash Flow from Operations NASHVILLE, Tenn. , Nov. 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced to...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS
NASHVILLE, Tenn. , Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financia...
CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST
NASHVILLE, Tenn. , Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), the largest, public biopharmaceutical company founded and headquartered in Tennessee, announced today th...
Cumberland Pharmaceuticals Reports 14% Revenue Growth
Expanding portfolio of FDA approved brands driving double digit growth NASHVILLE, Tenn. , Aug. 9, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical compan...
CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021
The company's annual sustainability report highlights its continued focus on and commitment to environmental, social and governance issues NASHVILLE, Tenn. , Aug. 8, 2022 /PRNewswire/ -- Cumberland Ph...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS
NASHVILLE, Tenn. , Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financi...
CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS
NASHVILLE, Tenn. , July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Boar...
Cumberland Pharmaceuticals Reports 6% Revenue Growth
The Nashville-based specialty pharmaceutical company issues first quarter 2022 financial results and a company update NASHVILLE, Tenn. , May 10, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (...
Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®
Verity Pharmaceuticals will feature Sancuso across the U.S. through its established oncology commercial organization and customer network NASHVILLE, Tenn. , May 9, 2022 /PRNewswire/ -- Specialty phar...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2022 FINANCIAL RESULTS
NASHVILLE, Tenn. , May 3, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2022 financia...